Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
01 nov. 2022 17h29 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
12 oct. 2022 07h30 HE
|
Fulcrum Therapeutics, Inc.
- 96-week findings support losmapimod as a disease-modifying therapy for FSHD - U.S. Food and Drug Administration (FDA) granted Fast Track Designation in 2021 - Industry Symposium on October 12,...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 oct. 2022 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 sept. 2022 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences
06 sept. 2022 16h01 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit
16 août 2022 07h05 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
15 août 2022 21h28 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
15 août 2022 16h08 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
11 août 2022 07h00 HE
|
Fulcrum Therapeutics, Inc.
Presented initial data from Phase 1b trial in sickle cell disease (SCD), which demonstrate rapid and robust increases in hemoglobin F (HbF); supports proof-of-concept that FTX-6058 is a novel oral HbF...
Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET
04 août 2022 08h07 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...